Stock of the Day

November 25, 2024

Exact Sciences (EXAS)

$104.91
$0.00 (0.0%)
Market Cap: $20.03B

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Today's Trend

Exact Sciences (EXAS) — Shares moved on heavy volume after market-moving takeover headlines: Abbott (ABT) has completed its acquisition of Exact Sciences, bringing EXAS’s flagship colorectal‑cancer screening test, Cologuard, into Abbott’s portfolio. Below are the items most likely driving the stock action and what investors should watch next.

  • Abbott completed the acquisition of Exact Sciences, a cash takeover reported in the $21–$23 billion range; the deal transfers Cologuard and Exact’s screening business to Abbott, which typically implies a buyout premium for EXAS shareholders. Abbott completes acquisition of Exact Sciences
  • Local reporting confirms the transaction close and reiterates deal valuation (~$23B in some reports); this is corroborating coverage rather than new terms, so it mainly reinforces the takeover rationale. Abbott closes $23 billion deal to buy Madison-based Exact Sciences
  • An alternate outlet reported a $21 billion figure for the transaction — a discrepancy in headlines that can create short‑term price noise but does not change the fact of the acquisition closing. Abbott (ABT) Finalizes $21 Billion Exact Sciences (EXAS) Takeover
  • Trading in EXAS was temporarily halted before the announcement for "News pending," consistent with an imminent corporate action; halts are routine ahead of M&A prints but can amplify intraday volatility.
  • BTIG reiterated a "neutral" rating on EXAS earlier — a hold-type view that is now secondary to the acquisition close, though it may matter for pre-close trading context. BTIG Research reaffirms neutral on Exact Sciences
  • Several short‑interest reports posted odd entries showing 0 shares and NaN changes — this appears to be a data glitch rather than evidence of new shorting activity, so it’s unlikely to be a reliable signal.

What investors should monitor: settlement/tender mechanics and the announced per‑share consideration, timing for cash payments or delisting, and any regulatory or integration commentary from Abbott that could affect related diagnostics names. With the deal reported as closed, EXAS shareholders should expect buyout execution details to determine final cash flows and timing.

← Previous Stock of the DayNext Stock of the Day →